Under the agreement, the Alliance will provide up to $1.6 million towards the development of the OPGx- RDH12 program. The partnership also includes a risk-sharing structure and performance-based milestones. Together, the parties will co-develop the OPGx-RDH12 program, including the clinical and regulatory strategy, with the goal of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by late 2025. "Since founding the RDH12 Fund for Sight more than a decade ag ...